MX2010010334A - Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. - Google Patents
Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.Info
- Publication number
- MX2010010334A MX2010010334A MX2010010334A MX2010010334A MX2010010334A MX 2010010334 A MX2010010334 A MX 2010010334A MX 2010010334 A MX2010010334 A MX 2010010334A MX 2010010334 A MX2010010334 A MX 2010010334A MX 2010010334 A MX2010010334 A MX 2010010334A
- Authority
- MX
- Mexico
- Prior art keywords
- oxoisoindoline
- carboxamide
- methoxyphenyl
- cyclopropyl
- ethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Se describen métodos de tratamiento, manejo o prevención de psoriasis o artritis psoriática. Los métodos engloban la administración de ciclopropil-N-(2-[(1S)-1-(3-etoxi-4-metoxifenil) -2-(metilsulfonil)etil]-3-oxoisoindolina-4-il}carboxamida, sola o en combinación con un segundo agente activo. También se describen composiciones farmacéuticas y formas de dosificación unitaria sencillas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7051408P | 2008-03-24 | 2008-03-24 | |
PCT/US2009/001805 WO2009120296A1 (en) | 2008-03-24 | 2009-03-23 | Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010010334A true MX2010010334A (es) | 2010-10-08 |
Family
ID=40642701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010010334A MX2010010334A (es) | 2008-03-24 | 2009-03-23 | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090239926A1 (es) |
EP (1) | EP2268279A1 (es) |
JP (1) | JP2011515469A (es) |
CN (1) | CN102036663A (es) |
CA (1) | CA2718412A1 (es) |
MX (1) | MX2010010334A (es) |
WO (1) | WO2009120296A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY183201A (en) * | 2009-10-09 | 2021-02-18 | Celgene Corp | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds |
US20110318741A1 (en) * | 2010-06-15 | 2011-12-29 | Schafer Peter H | Biomarkers for the treatment of psoriasis |
US9757355B2 (en) | 2011-01-10 | 2017-09-12 | Celgene Corporation | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide |
CN103635188B (zh) * | 2011-04-28 | 2017-03-22 | 细胞基因公司 | 使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物 |
MX356105B (es) * | 2011-09-14 | 2018-05-14 | Celgene Corp | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. |
US9872854B2 (en) | 2013-03-14 | 2018-01-23 | Celgene Corporation | Methods for the treatment of psoriatic arthritis using apremilast |
WO2016025686A1 (en) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
WO2019186561A1 (en) * | 2018-03-29 | 2019-10-03 | S.I.S Shulov Innovative Science Ltd. | Pharmaceutical compositions for inhibiting inflammatory cytokines |
CN114767665B (zh) * | 2021-06-11 | 2023-10-10 | 同济大学 | 5-十四烷氧基-2-呋喃甲酸在制备用于治疗银屑病样皮炎的药物中的用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
US3322755A (en) * | 1964-03-10 | 1967-05-30 | Boehringer Sohn Ingelheim | Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines |
JPS4966691A (es) * | 1972-10-30 | 1974-06-27 | ||
CH598013A5 (es) * | 1974-11-13 | 1978-04-28 | Ciba Geigy Ag | |
US4162316A (en) * | 1975-03-12 | 1979-07-24 | Dainippon Pharmaceutical Co., Ltd. | 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same |
US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
US4001238A (en) * | 1976-02-18 | 1977-01-04 | Bristol-Myers Company | 1,3,4-oxadiazole amides |
US4047404A (en) * | 1976-11-17 | 1977-09-13 | Tanno Senshoku Kogyo Co., Ltd. | Printed fabric washing apparatus |
US4101548A (en) * | 1977-02-22 | 1978-07-18 | Bristol-Myers Company | 1,2,3-Thiadiazole amides |
US4209623A (en) * | 1978-06-07 | 1980-06-24 | Bristol-Myers Company | Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides |
DE3770095D1 (de) * | 1986-08-21 | 1991-06-20 | Pfizer | Chinazolindione und pyridopyrimidindione. |
CA1303037C (en) * | 1987-02-02 | 1992-06-09 | Smith Kline & French Laboratories Limited | Purinone derivatives as bronchodilators vasodilators and anti-allergic agents |
GB8827988D0 (en) * | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
US5401774A (en) * | 1991-03-08 | 1995-03-28 | University Of Arizona | Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds |
US5354571A (en) * | 1992-04-27 | 1994-10-11 | Rheon Automatic Machinery Co., Ltd. | Method for aligning and bending individual round elongated dough pieces |
JP2657760B2 (ja) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5614627A (en) * | 1993-09-10 | 1997-03-25 | Eisai Co., Ltd. | Quinazoline compounds |
US5608914A (en) * | 1994-11-21 | 1997-03-11 | Keesler; Daren | Headcover |
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US5614530A (en) * | 1995-03-10 | 1997-03-25 | Sterling Winthrop Inc. | Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof |
US5488055A (en) * | 1995-03-10 | 1996-01-30 | Sanofi Winthrop Inc. | Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof |
ATE219765T1 (de) * | 1995-04-10 | 2002-07-15 | Fujisawa Pharmaceutical Co | Indolderivate als cgmp-pde inhibitoren |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
US5710170A (en) * | 1995-12-15 | 1998-01-20 | Merck Frosst Canada, Inc. | Tri-aryl ethane derivatives as PDE IV inhibitors |
GB9526245D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526246D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526243D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
ES2302350T3 (es) * | 1997-02-28 | 2008-07-01 | Nycomed Gmbh | Combinacion sinergica de inhibidores de pde y agonistas de adenilatociclasa o agonistas de guanililciclasa. |
US6034089A (en) * | 1997-10-03 | 2000-03-07 | Merck & Co., Inc. | Aryl thiophene derivatives as PDE IV inhibitors |
US6020339A (en) * | 1997-10-03 | 2000-02-01 | Merck & Co., Inc. | Aryl furan derivatives as PDE IV inhibitors |
AU751453C (en) * | 1997-11-25 | 2003-04-10 | Warner-Lambert Company | Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6025394A (en) * | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
CA2364653A1 (en) * | 1999-02-25 | 2000-08-31 | Merck Frosst Canada & Co. | Pde iv inhibiting compounds, compositions and methods of treatment |
US6316472B1 (en) * | 1999-05-13 | 2001-11-13 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE 4 inhibitors |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
ES2436606T3 (es) * | 2003-03-12 | 2014-01-03 | Celgene Corporation | Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos |
JP2007536222A (ja) * | 2004-05-05 | 2007-12-13 | セルジーン・コーポレーション | 癌及び他の疾患を治療及び管理するための選択的サイトカイン阻害薬を用いた方法及び組成物 |
-
2009
- 2009-03-23 MX MX2010010334A patent/MX2010010334A/es not_active Application Discontinuation
- 2009-03-23 WO PCT/US2009/001805 patent/WO2009120296A1/en active Application Filing
- 2009-03-23 CN CN200980118665XA patent/CN102036663A/zh active Pending
- 2009-03-23 CA CA2718412A patent/CA2718412A1/en not_active Abandoned
- 2009-03-23 JP JP2011501796A patent/JP2011515469A/ja not_active Withdrawn
- 2009-03-23 EP EP09724498A patent/EP2268279A1/en not_active Withdrawn
- 2009-03-24 US US12/410,011 patent/US20090239926A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102036663A (zh) | 2011-04-27 |
JP2011515469A (ja) | 2011-05-19 |
US20090239926A1 (en) | 2009-09-24 |
CA2718412A1 (en) | 2009-10-01 |
WO2009120296A1 (en) | 2009-10-01 |
EP2268279A1 (en) | 2011-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010010334A (es) | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. | |
IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
MX2007006063A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central. | |
MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
UA97795C2 (uk) | Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
MX2013013809A (es) | Dispositivos expandibles con revestimiento de una composicion de paclitaxel. | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
TW200733961A (en) | Diaryl urea for treating pulmonary hypertension | |
HK1121936A1 (en) | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | |
SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
WO2009067856A8 (zh) | 组蛋白去乙酰化酶抑制剂及其制备和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |